MG132,蛋白酶体抑制剂

概述作用体外活性体内活性生物活性靶点体外研究体内研究 MG132,蛋白酶体抑制剂试剂级价格

MG132,蛋白酶体抑制剂

CAS号:133407-82-6
英文名:MG-132
中文名:MG132,蛋白酶体抑制剂
CBNumber:CB3298042
分子式:C26H41N3O5
分子量:475.62
MOL File:133407-82-6.mol

MG132,蛋白酶体抑制剂化学性质

熔点 :80-84℃ (DEC.)
比旋光度 :-61～-67°
沸点 :682.0±55.0 °C(Predicted)
密度 :1.073
闪点 :366℃
储存条件 :-20°C
溶解度 :methanol: 1 mg/mL
形态 :solid film
酸度系数(pKa) :11.14±0.46(Predicted)
颜色 :White
水溶解性 :Soluble in ethanol, chloroform, methanol, water.
稳定性 :Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF or ethanol may be stored at -20° for up to 1 week.
InChIKey :TZYWCYJVHRLUCT-VABKMULXSA-N

安全信息

危险类别码 :36/37/38
安全说明 :24/25
WGK Germany :3
海关编码 :29242990

MG132,蛋白酶体抑制剂性质、用途与生产工艺

概述
MG132,蛋白酶体抑制剂是一种有效，可逆，能渗透细细胞的20S蛋白酶抑制剂。它抑制蛋白酶体胰凝乳蛋白酶样肽酶活性的 IC50值为24.2 nM。MG-132以时间和剂量依赖性方式抑制问C6神经胶质瘤细胞增殖（24小时时的IC 50值为18.5μM）。 MG-132通过下调抗细胞凋亡答蛋白Bcl-2和XIAP，促内凋亡蛋白Bax和半胱天冬酶-3的上调以及切割的C端85kDa PARP的产生来诱导细胞凋亡。
作用 MG-132是一种多肽醛，也是有效的，可逆的，可透过细胞的蛋白酶体抑制剂，IC50 值为 100 nM，有效地阻断了 26S 蛋白酶体复合物的蛋白水解活性。
体外活性
MG132通过诱导细胞周期停滞以及引发细胞凋亡来抑制HeLa细胞的生长。 MG-132以时间和剂量依赖性方式抑制C6神经胶质瘤细胞增殖（24小时时的IC 50值为18.5μM）。 MG-132（18.5μM）在3小时时抑制蛋白酶体活性约70％。MG-132通过下调抗细胞凋亡蛋白Bcl-2和XIAP，促凋亡蛋白Bax和半胱天冬酶-3的上调以及切割的C端85kDa PARP的产生来诱导细胞凋亡。 MG-132还会使活性氧增加5倍以上。孵育48小时后MG-132对HeLa，CaSki和C33A宫颈癌细胞存活率的IC50分别为2.1,3.2和5.2μM。
体内活性
使用皮下注射检查MG-132对宫颈癌的体内抗肿瘤活性。异种移植模型。使用以下方案以1mg / kg注射MG-132：对于携带HeLa肿瘤的小鼠，第1,4,8,12,15,18,23和26天。与对照相比，MG132的生长抑制率为49％。 MG-132（腹股沟，0.1 mg / kg /天）通过调节ERK1 / 2和JNK1信号通路减轻压力超负荷引起的心脏肥大并改善腹主动脉条带（AAB）大鼠的心脏功能。
生物活性 MG-132 (Z-Leu-Leu-Leu-al) 是一种有效的，可逆的蛋白酶体 (proteasome) 抑制剂，IC50 为 100 nM。MG-132 有效阻断 26S 蛋白酶体复合物的蛋白水解活性。MG-132 是一种肽醛，是自噬 (autophagy) 激活剂。MG-132 还诱导凋亡 (apoptosis)。
靶点

IC50: 100 nM (Proteasome), 1.2 μM (Calpain)

体外研究

MG-132 (Z-Leu-Leu-Leu-al) initiates neurite outgrowth in PC12 cells at a low concentration (30 nM) and is a very strong inhibitor of 20S proteasome.
MG-132 (10 μM; 1 hour) reverses the effects of TNF- α on I κ B degradation and NF-κ B activation in A549 cells.
MG-132 (0.75-5 μM; 24 hours) potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition.
MG-132 (10-40 μM; 24 hours) significantly reduces the viability of C6 glioma cells in both time- and concentration-dependent manners and shows the IC ₅₀ of 18.5 μM at 24 hours.
MG-132 (18.5 μM; 24 hours) induces down-regulation of anti-apoptotic proteins Bcl-2 and XIAP and up-regulates expression of pro-apoptotic protein Bax and caspase-3.

Cell Viability Assay

Cell Line:	C6 glioma cells
Concentration:	10, 20, 30, 40 μM
Incubation Time:	24 hours
Result:	Significantly reduced the viability of C6 glioma cells beginning at 6 h in both time- and concentration-dependent manners and showed the IC ₅₀ of 18.5 μM at 24 hours.

Western Blot Analysis

Cell Line:	A549 cells
Concentration:	10 μM
Incubation Time:	1 hour
Result:	Reversed the effects of TNF-α on IκB degradation and resulted in a reversal of TNF-α-induced NF-κB activation.

体内研究

MG132 (10 mg/kg; i.p.; daily for 25 days starting 5 days after EC9706 cells injection) significantly inhibits tumor growth of the EC9706 xenograft without causing toxicity to mice.
MG-132 (1 mg/kg; i.v.; twice a week for 4 weeks) shows potent tumor inhibitory effect against mice bearing HeLa tumors.
MG-132 (1-10 μg/kg/24 hours; subcutaneously implanted osmotic pumps; for 8 days) greatly increases the expression levels of β-dystroglycan, α-dystroglycan, α-sarcoglycan, and dystrophin in skeletal muscle lysates in mice (six-month-old male C57BL/10ScSn DMD mdx mice).

Animal Model:	5- to 6-weeks old female athymic nude mice (EC9706 xenograft)
Dosage:	10 mg/kg
Administration:	I.p.; daily for 25 days starting 5 days after EC9706 cells injection
Result:	Significantly inhibited tumor growth of the EC9706 xenograft without causing toxicity to the mice.

Animal Model:	Five-week-old female C.B-17/lcr-scid/scidJcl mice (bearing HeLa cells)
Dosage:	1 mg/kg
Administration:	Intravenous injection; twice a week for 4 weeks
Result:	The growth inhibition rates in HeLa tumors was 49% compared to the control.